The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 27, 2021

Filed:

Sep. 21, 2015
Applicant:

Shenzhen Evergreen Therapeutics Co., Ltd., Shenzhen, CN;

Inventors:

Tao Tom Du, North Potomac, MD (US);

Chang Lee, Bethesda, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 31/58 (2006.01); A61K 31/57 (2006.01); A61K 31/56 (2006.01);
U.S. Cl.
CPC ...
A61K 31/573 (2013.01); A61K 9/0075 (2013.01); A61K 9/0078 (2013.01); A61K 31/56 (2013.01); A61K 31/57 (2013.01); A61K 31/58 (2013.01);
Abstract

The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.


Find Patent Forward Citations

Loading…